Sahajanand Medical Technologies Limited (SMT) is an India-based medical devices company founded in 2001. It researches, designs, develops, manufactures and markets vascular devices globally, focusing on high-quality products offered at market-appropriate prices and supported by clinical data. The company has direct and distributor sales operations in more than 69 countries, including Germany, Poland, Spain, France, the UK and Brazil.
SMT’s portfolio covers three key segments: Interventional Cardiology, including coronary stents and catheters for treating heart-vessel blockages; Structural Heart Therapy, including transcatheter aortic valve implants and occluders; and Peripheral Intervention, including renal stents for treating blockages outside the heart. Its flagship coronary product is Supraflex Cruz. Other products include Renofit, a cobalt chromium renal and biliary stent system, and products obtained through its expansion into structural heart therapy.
The company operates three manufacturing facilities in Surat and Bengaluru, India, serving the interventional cardiology and peripheral intervention businesses, and one facility in Nonthaburi, Thailand, manufacturing structural heart therapy products. Its international expansion has included acquisitions and partnerships in Spain, Brazil and India, as well as direct operations in several European markets. As of March 31, 2021, SMT had direct operations in 10 countries and distributor sales across more than 59 countries through 67 distributors.
SMT has introduced products such as biodegradable polymer drug-eluting stents and low-strut-thickness stents, and has conducted clinical trials comparing its products with leading global competitors. The company planned an initial public offering of up to ₹1,500 crore, comprising a fresh issue of up to ₹410.33 crore and an offer for sale of up to ₹1,089.67 crore.
